AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05828069 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FDG-Positron Emission Tomography and Computed Tomography Scan
Description: Undergo FDG-PET imaging
Study NCT06517914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH35995
Description: Oral administration of YH35995
Study NCT05828069 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Undergo lumbar puncture
Study NCT05828069 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study NCT05828069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tovorafenib
Description: Given PO
Study NCT06517914 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of Placebo
Study NCT05738434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab+Apatinib+Chemotherapy→Camrelizumab+Apatinib
Description: camrelizumab 200 mg, i.v. d1,q3w; apatinib 250 mg, p.o. qd,q3w; cisplatin 25 mg/m2, i.v. d1-d3,q3w; According to investigator' choice： paclitaxel 135\~150 mg/m2, i.v. d1,q3w; paclitaxel-albumin 150\~180 mg/m2, i.v. d1,q3w. up to 4 cycles and sequential maintenance therapy： camrelizumab 200 mg, i.v. d1,q3w; apatinib 250 mg, p.o. qd,q3w
Study NCT05738434 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Camrelizumab+Chemotherapy→Camrelizumab
Description: camrelizumab 200 mg, i.v. d1,q3w; cisplatin 25 mg/m2, i.v. d1-d3,q3w; According to investgator' choice： paclitaxel 175 mg/m2, i.v. d1,q3w; paclitaxel-albumin 200 mg/m2, i.v. d1,q3w up to 6 cycles and sequential maintenance therapy： camrelizumab 200 mg, i.v. d1,q3w;
Study NCT05995262 — intervention group
Intervention type: OTHER
Intervention: Chart Review
Description: Data collection via retrospective chart review of patients from the Cedar Hill Clinic who had at least two visits with the clinical pharmacist between January 5, 2022 through December 31, 2022
Study NCT05357820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB-106, Itraconazole
Description: single dose AB-106 at Day1, Itraconazole QD at Day14\~Day28, single dose AB-106 at Day17
Study NCT05357820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB-106, Rifampicin
Description: single dose AB-106 at Day1, Itraconazole QD at Day14\~Day32, single dose AB-106 at Day21
Study NCT06171711 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure Therapy
Description: The proposed study will explore whether Exp-AN works via inhibitory learning (i.e., decreasing anxious beliefs and increasing anxiety tolerance) and/or between-session habituation (i.e., decreasing anxiety levels across therapy sessions), and the importance of targeting anxiety about eating versus weight gain. Results will provide information about the degree to which all three mechanisms of action (i.e., changes in anxiety ratings, anxious beliefs, and tolerance of anxiety) predict improved AN symptomatology across both treatments. Research that discovers whether specific treatments (e.g., Exp-AN) work in the way the investigators think they do (e.g., by increasing tolerance of anxiety), and whether modifying intervention targets (e.g., tolerance of anxiety) helps people get better (e.g., reduced AN symptomatology), will ultimately lead to more personalized, mechanism-based, and effective treatments (Insel 2014; Insel et al., 2010).
Study NCT05026996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pelacarsen
Description: Single subcutaneous injection of pelacarsen
Study NCT04731246 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video-oculography / Neuropsychological evaluations
Description: Annual evaluation: Medical history; Clinical, Neurological and Neuropsychological evaluations; Video-oculography examination; Inventory of examinations carried out in routine care (brain MRI, cerebral DaTScan, cerebral F-Dopa PET/CT scan, MIBG myocardial scintigraphy, blood test). Follow-up is carried out over 7 years.
Study NCT06548815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZR4
Description: Ascending single doses - 4 dose levels.
Study NCT06548815 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ascending single doses - 4 dose levels.
Study NCT05713799 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05713799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirabegron
Description: selective beta3-AR agonist approved
Study NCT05713799 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mirabegron
Description: selective beta3-AR agonist approved
Study NCT05713799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alpha-lipoic acid
Description: ALA is an antioxidant that is available over the counter
Study NCT06427928 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Explains the perioperative process with pictures
Description: We will draw pictures of the preoperative area, operating room and postoperative areas of our operating room and explain the process to 34 of the children who will undergo surgery with these pictures. We will explain the process to the other 34 people without the pictures we have. We planned to measure the anxiety levels between the two groups with the modified Yale scale.
Study NCT06427928 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Explains the perioperative process with pictures
Description: We will draw pictures of the preoperative area, operating room and postoperative areas of our operating room and explain the process to 34 of the children who will undergo surgery with these pictures. We will explain the process to the other 34 people without the pictures we have. We planned to measure the anxiety levels between the two groups with the modified Yale scale.
Study NCT06427928 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The perioperative process is only explained
Description: We will draw pictures of the preoperative area, operating room and postoperative areas of our operating room and explain the process to 34 of the children who will undergo surgery with these pictures. We will explain the process to the other 34 people without the pictures we have. We planned to measure the anxiety levels between the two groups with the modified Yale scale.
Study NCT06427928 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: The perioperative process is only explained
Description: We will draw pictures of the preoperative area, operating room and postoperative areas of our operating room and explain the process to 34 of the children who will undergo surgery with these pictures. We will explain the process to the other 34 people without the pictures we have. We planned to measure the anxiety levels between the two groups with the modified Yale scale.
Study NCT04507178 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nadroparin Injectable Product
Description: high dose LMWH compared to prophylactic dose LMWH
Study NCT05090683 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-body mobile application
Description: Self-directed; Study team will recommend daily use of mobile app for 6 weeks with a minimum of 4 times/week usage of mobile app for 6 weeks. Frequency will be monitored via weekly surveys.
Study NCT05353439 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT05353439 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood
Study NCT05353439 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT05353439 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT05353439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat Hydrobromide
Description: Given PO
Study NCT05353439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan Hydrochloride
Description: Given IV
Study NCT06455241 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HABIT (Hand Activities Behavior Intervention)
Description: A Novel Occupational Therapy Intervention for Enhancing Daily Hand-Use of the affected upper extremity Among Individuals post Stroke.
Study NCT05359445 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMA401 (Phase Ia)
Description: Intravenous infusions in escalating dose levels
Study NCT05359445 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (Phase Ia)
Description: Intravenous infusions in escalating dose levels for combination of IMA 401 and Pembrolizumab
Study NCT05359445 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMA 401 (Phase Ib)
Description: Treatment at recommended dose for extension (RDE)
Study NCT05411081 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV
Study NCT05411081 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood and urine samples
Study NCT05411081 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood and urine samples
Study NCT05411081 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Scan
Description: Undergo bone scans
Study NCT05411081 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scans
Study NCT05411081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabozantinib S-malate
Description: Given PO
Study NCT05411081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO
Study NCT05411081 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT scans
Study NCT05411081 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scans
Study NCT05411081 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05411081 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05276063 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linsitinib
Description: Study medication taken twice daily by mouth
Study NCT05276063 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo taken twice daily by mouth
Study NCT06161688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ensitrelvir
Description: Those randomized to the experimental arm will receive Ensitrelvir, a protease inhibitor, taken orally for 5 days
Study NCT06161688 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo for Ensitrelvir
Study NCT05565950 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AI-09
Description: Botulinum toxin, Type A, intramuscular injection, administered once at baseline
Study NCT05565950 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle Formulation
Study NCT05691738 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Group
Description: The exercise group will be informed about diabetes and diabetes complications. A total of 16 sessions of 8 weeks, modified otago exercises will be applied individually by the research physiotherapist.Individuals will be allowed to walk at a moderate pace for at least 30 minutes 5 days a week (home program).
Study NCT05691738 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: The control group will be informed about diabetes and diabetes complications. Individuals will be allowed to walk at a moderate pace for at least 30 minutes 5 days a week (home program)
Study NCT05695131 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GlenXRose Virtual Reality Speech Therapies
Description: Speech therapies for vocal cord disorders have been developed for virtual reality implementation. These include various games to interact with in a virtual environment while conducting rehabilitation therapy, in addition to educational visualizations
Study NCT05292924 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early SCC
Description: Direct, immediate and uninterrupted contact of the infant with its mother's skin first 30 minutes delivery
Study NCT04840485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1314
Description: SHR-1314 high dose
Study NCT04840485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1314
Description: SHR-1314 low-dose
Study NCT04840485 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04803305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06946860
Description: subcutaneous injection
Study NCT04803305 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PF-06946860
Description: subcutaneous injection
Study NCT04803305 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for PF-06946860
Description: subcutaneous injection
Study NCT04297033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovastatin
Description: lovastatin 40mg/d 12m
Study NCT04297033 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT05458882 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: living with food allergy educational booklet
Description: An educational booklet giving information on social and eating out habits as well as reaction rates in food allergy Irish children.
Study NCT06157632 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Thyriodectomy
Description: Thyroidectomy
Study NCT06582706 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: a readily available inert placebo will be used
Study NCT06582706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended Release Niacin
Description: 500 mg
Study NCT05194111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril-valsartan
Description: Administered orally twice daily at a maximally tolerate dose (max dose 97mg/103mg twice daily).
Study NCT05343351 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Technique of injection method
Description: In 'out of plane group', the ultrasound probe will be placed at the entrance level of the proximal carpal tunnel (scaphoid-pisiform plane), the ulnar edge of the median nerve will be taken to the midpoint of the probe, and then the needle will be inserted from the middle point of the probe with the out of plane method. Then the needle will be advanced towards the ulnar side of the median nerve and the injection content will be given into the tunnel.~In 'in plane group group', the ultrasound probe will be placed at the proximal carpal tunnel entrance level (scaphoid-pisiform plane), it will be entered at a cross angle between the ulnar artery and the median nerve with the in-plane method, and be advanced under the median nerve, and then the injection content will be given into the carpal tunnel.
Study NCT05380089 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Increasing water intake
Description: Participants randomly assigned to the experimental group will be instructed to maintain habitual solid food choices and to increase water intake to achieve a total water intake of ≥45ml/kg/day.
Study NCT05470088 — intervention group
Intervention type: OTHER
Intervention: Neuroimaging (MRI)
Description: Multimodal magnetic resonance imaging
Study NCT06562907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-4571
Description: Administered orally
Study NCT06562907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally
Study NCT06562907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Administered orally
Study NCT05127967 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Skin biopsy
Description: A skin biopsy involves taking a piece of skin to obtain cells (fibroblasts). Skin biopsy is a minimally invasive examination and a technically simple procedure performed with a 3mm diameter punch, or with a scalpel under local anesthesia (Lidocaine patch). The procedure can be done in a consultation office with strict asepsis. It lasts 15 minutes in total + the time to reach between putting on the lidocaine patch and performing the procedure. This biopsy will usually be done on the inside of the arm. In the majority of cases, it is not helpful to close the scar with stitches.
Study NCT05610787 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EXCOR Active Driving System for Pediatric VAD
Description: The EXCOR Active Driving System - will be used with the EXCOR Pediatric VAD.
Study NCT05157113 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dropless Regimen
Description: Intraoperative subconjunctival injection of triamcinolone acetonide (20mg) delivered 4-5 mm posterior to the limbus at the end of surgery.~Intraoperative intracameral injection of cefuroxime delivered at the end of surgery.~No postoperative drops.
Study NCT05157113 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Regimen
Description: Intraoperative intracameral injection of cefuroxime delivered at the end of surgery.~Neomycin/Polymyxin B ophthalmic solution: one drop to the operative eye four times daily for 1 week, then stop.~Ketorolac 0.5% ophthalmic solution: one drop to the operative eye four times daily for 1 month or until the bottle runs out.~Prednisolone acetate 1% ophthalmic solution: one drop to the operative eye four times daily for 1 month, then stop.
Study NCT05194111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: Administered orally twice daily at a maximally tolerate dose (max dose 160mg twice daily)
Study NCT06238531 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gusacitinib
Description: An orally active dual SYK/JAK kinase inhibitor
Study NCT06303544 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wedge 1
Description: Wedge1 will receive intervention consisting of culturally based physical activity module, built environment, community healthy lifestyle promotion
Study NCT06153290 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chiropractic adjustment
Description: A single-session of genuine/real high-velocity, low-amplitude (HVLA) manual chiropractic adjustments to various regions of the spine (i.e., cervical, thoracic, lumbo-pelvic)
Study NCT06153290 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham adjustment
Description: A single-session of simulated/sham high-velocity, low-amplitude (HVLA) manual chiropractic adjustments to various regions of the spine (i.e., cervical, thoracic, lumbo-pelvic)
Study NCT05098405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP0317, a tri-specific fibroblast activation protein (FAP) x CD40 DARPin® drug candidate (q3w regimen)
Description: The study will start with dose-escalation cohorts to determine the recommended dose for expansion (RDE) or the maximum tolerated dose (MTD).~Once the RDE (or MTD) has been determined, a safety expansion cohort will be opened and additional patients will be treated with MP0317 monotherapy at this dose to confirm safety in a larger population.~Study treatment will be administered every 3 weeks (q3w) as an intravenous (IV) infusion until progressive disease (PD), unacceptable toxicity, withdrawal of consent or other reasons to discontinue treatment occur, whichever comes first. Treatment beyond PD will be allowed as per Immunotherapy Response Evaluation Criteria in Solid Tumors (iRECIST).
Study NCT05098405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP0317, a tri-specific fibroblast activation protein (FAP) x CD40 DARPin® drug candidate (q1w regimen)
Description: The study will start with dose-escalation cohorts to determine the recommended dose for expansion (RDE) or the maximum tolerated dose (MTD).~Once the RDE (or MTD) has been determined, a safety expansion cohort will be opened and additional patients will be treated with MP0317 monotherapy at this dose to confirm safety in a larger population.~Study treatment will be administered every week (q1w) as an intravenous (IV) infusion until progressive disease (PD), unacceptable toxicity, withdrawal of consent or other reasons to discontinue treatment occur, whichever comes first. Treatment beyond PD will be allowed as per Immunotherapy Response Evaluation Criteria in Solid Tumors (iRECIST).
Study NCT06412991 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cycle Therapy
Description: The patient will either ambulate a short distance to recumbent bike which will be stored on the postsurgical 1 unit or be assisted out of bed to use floor cycle bike.
Study NCT06330116 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IQoro
Description: Please refer to arm/group description for information
Study NCT06330116 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: eXciteosa
Description: Please refer to arm/group description for information
Study NCT06330116 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Grouptraining
Description: Please refer to arm/group description for information